



Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 016915-0244		SERIAL NO. 09/914,270	
				APPLICANT Gerd GEISLINGER et al.			
				FILING DATE 08/24/2001		GROUP ART UNIT Unassigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
MA	A1	5,200,198	April 6, 1993	Geisslinger et al.	424	489	
MA	A2	5,206,029	April 27, 1993	Brune et al.	424	489	
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
MA	A3	0 607 128	Sept. 17, 1997	EPO			Abstract
	A4	40 28 906	Oct. 29, 1992	Fed. Rep. of Germany	} abstract only		Abstract
	A5	43 19 438	June 1, 1994	Fed. Rep. of Germany			Abstract
	A6	197 16 713	Oct. 22, 1998	Fed. Rep. of Germany			Abstract
MA	A7	93/17677	Sept. 16, 1993	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
MA	A8	Hardman et al., "The Pharmacological Basis of Therapeutics," Chapter 27: Analgesic-Anti-pyretic and Antiinflammatory Agents – Propionic Acid Derivatives (1996), pp. 637-639.					
	A9	Williams, "Enantiomers in Arthritic Disorders," Pharmac. Ther., Vol. 46 (1990), pp. 273-295.					
	A10	Evans, "Enantioselective Pharmacodynamics and Pharmacokinetics of Chiral Non-Steroidal Anti-Inflammatory Drugs," Eur. J. Clin Pharmacol., Vol. 42 (1992), pp. 237-256.					
	A11	"Symposium: Update on S(+)-Ibuprofen," Going/Kitsbuehel (1996).					
	A12	"Menarini/Chiros S-Ketoprofen Deal," SCRIP No. 1831 (June 22, 1993), p. 7.					
	A13	"First Launch for Dexketoprofen," SCRIP No. 2144 (July 9, 1996), p. 16.					
	A14	Vane et al., "Overview – Mechanisms of Action of Anti-Inflammatory Drugs," Improved Non-Steroidal Anti-Inflammatory Drugs – COX-2 Enzyme Inhibitors (1996), pp. 1-27.					
	A15	Williams et al., "Stereoselective Disposition – Basis for Variability in Response to NSAID's," Non-Steroidal Anti-Inflammatory Drugs Basis for Variability in Response (May 1985), pp. 119-126.					
MA	A16	Caldwell et al., "The Metabolic Chiral Inversion and Dispositional Enantioselectivity of the 2-Arylpropionic Acids and their Biological Consequences," Biochemical Pharmacology, Vol. 37, No. 1 (1988), pp. 105-114.					
EXAMINER 				DATE CONSIDERED 05/01/03			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
016915-0244SERIAL NO.
09/914,270

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Gerd GEISSLINGER et al.

FILING DATE

08/24/2001

GROUP ART UNIT

Unassigned

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
MB	A25	98/47502	Oct. 29, 1998	WIPO				
MB	A26	98/09603	March 12, 1998	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MB	A17	Villanueva et al., "Equipotent Inhibition by R(-), S(+)- and Racemic Ibuprofen of Human Polymorphonuclear Cell Function <i>in vitro</i> ," Br. J. Clin. Pharmac., Vol. 35 (1993), pp. 235-242.						
	A18	Geisslinger et al., "New Insights into the Site and Mode of Antinociceptive Action of Flurbiprofen Enantiomers," The Journal of Clinical Pharmacology, Vol. 36, No. 6 (June 1996), pp. 513-520.						
	A19	Buritova et al., "Peripheral and/or Central Effects of Racemic-, S(+)- and R(-)-Flurbiprofen on Inflammatory Nociceptive Processes: a c-Fos Protein Study in the Rat Spinal Cord," British Journal of Pharmacology, Vol. 125 (1998), pp. 87-101.						
	A20	Cooper et al., "Analgesic Efficacy and Safety of (R)-Ketoprofen in Postoperative Dental Pain," J. Clin. Pharmacol., Vol. 38 (1998), pp. 11S-18S.						
	A21	Neugebauer et al., "Antinociceptive Effects of R(-)- and S(+)-Flurbiprofen on Rat Spinal Dorsal Horn Neurons Rendered Hyperexcitable by an Acute Knee Joint Inflammation," The Journal of Pharmacology and Experimental Therapeutics, Vol. 275, No. 2 (1995), pp. 618-628.						
	A22	Lee et al., "Nuclear Factor Kappa B: Important Transcription Factor and Therapeutic Target," J. Clin. Pharmacol., Vol. 38 (1998), pp. 981-993.						
	A23	Jerussi et al., "Clinical Endoscopic Evaluation of the Gastroduodenal Tolerance to (R)-Ketoprofen, (R)-Flurbiprofen, Racemic Ketoprofen, and Paracetamol: A Randomized, Single-Blind, Placebo-Controlled Trial," J. Clin. Pharmacol., Vol. 38 (1998), pp. 19S-24S.						
	A24	Meller et al., "Intraplantar Zymosan as a Reliable, Quantifiable Model of Thermal and Mechanical Hyperalgesia in the Rat," European Journal of Pain (1997), pp. 43-52.						
	A27	Sceuren, "Modulation of Transcription Factors by Nonsteroidal Anti-Inflammatory Drugs," Naunyn-Schmiedeberg's Arch. Pharmacol., Vol. 354, No. 4, Suppl. 1 (1996), p. R5.						
	A28	Scheuren, "Enantiomers of the Nonsteroidal Anti-Inflammatory Drug Ibuprofen are Potent and Specific Inhibitors of Transcription Factor NF-Kappa,beta," Naunyn-Schmiedeberg's Arch. Pharmacol., Vol. 357, No. 4 (1998), pp. R16.						
	A29	Scheuren, "Modulation of Transcription Factor NF-Kappa,beta by Enantiomers of the Nonsteroidal Drug Ibuprofen," Br. J. Pharmacol., Vol. 123, No. 4 (1998), pp. 645-652.						
MB	A30	Sceuren, "Week Inhibitors of Cyclooxygenases May Exert Their Antinociceptive Effect by Modulation of Transcription Factors," Adv. Exp. Med. Biol., Vol. 433 (1997), pp. 51-54.						